Caris Biopharma Solutions' comprehensive and integrated suite of biopharma services delivers value across your entire program life cycle—from development through launch and beyond. Discover more: https://lnkd.in/g_T42d33 #BiopharmaSolution #BioTech #PrecisionMedicine
Caris Life Sciences
Biotechnology Research
Irving, Texas 57,880 followers
Fulfilling the promise of precision medicine through quality and innovation.
About us
Caris Life Sciences® (Caris) is the leading next-generation TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale, clinico-genomic database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next-generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S., Europe, Asia and other international markets.
- Website
-
https://www.carislifesciences.com
External link for Caris Life Sciences
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Irving, Texas
- Type
- Privately Held
- Founded
- 1996
- Specialties
- Biotechnology, Molecular Profiling, Genomics, Personalized Medicine, Diagnostics, Theranostics, Panomics, Precision Medicine, and Comprehensive Genomic Profiling
Locations
-
Primary
750 W John Carpenter Fwy
Irving, Texas 75039, US
-
4610 S 44th Pl
Phoenix, Arizona 85040, US
-
St. Jakobsstrasse
199, 4052 Basel, CH
Employees at Caris Life Sciences
Updates
-
UVA Cancer Center joins Caris’ extensive network of leading cancer institutions and research consortia committed to improving patient outcomes through innovations in precision medicine. “We’re pleased to welcome UVA Cancer Center into the Caris Precision Oncology Alliance,” said George Sledge, Jr., MD, EVP and Chief Medical Officer of Caris. “We look forward to collaborating with their team of investigators on our shared mission of reducing the burden of cancer through research, education, patient care and community outreach.” Learn more: https://lnkd.in/gEt3HUDp
-
The availability of next-generation sequencing (NGS) technology helps open new avenues for cancer treatment. By incorporating insights from RNA expression profiling, we can optimize therapies to help meet the unique needs of each patient, enhancing the effectiveness of immunotherapy. Caris Life Sciences contributors Ari VanderWalde, MD, MPH, and Andrew Elliott, Ph.D., provide exciting insights into this collaborative research.
-
Subsets of colorectal cancer patients display different responses to targeted therapies. In collaboration with Caris Life Sciences, investigators at The University of Texas MD Anderson Cancer Center and their co-authors show how Consensus Molecular Subtyping can help identify patients most likely to experience clinical benefit from immune checkpoint blockade and anti-EGFR therapies. Learn more: https://lnkd.in/gfeS4t87 #CancerResearch #PrecisionMedicine #MolecularProfiling
-
Caris Life Sciences reposted this
Advances in biomarker testing, analytical methods, and real-world datasets that include biomarker and clinical data are rapidly enhancing precision oncology, enabling both forward and reverse translation and allowing for more effective patient-specific treatments. Join a panel of experts from Caris Life Sciences & University of Pennsylvania School of Medicine to explore the evolving state of precision oncology research and the pivotal role that high-quality linked clinical and multiomics RWD plays in accelerating all stages of drug development to maximize the success of novel therapeutics. ⬇️ Secure your spot & ask our panel of experts your questions directly. Register now: http://spkl.io/6046fJmSK
-
In celebration of #WorldCancerResearchDay, we are excited to showcase our Research & Development Laboratory in Phoenix. Caris’ commitment to leveraging advanced technologies and conducting innovative research is advancing cancer care and pioneering the next generation of precision medicine. Explore our work: https://lnkd.in/ghsfKdE5
-
Chat with our team at booth 508 during #AVAHO24 and learn why Caris Assure is a testament to our commitment to innovative patient solutions. Get more info: https://lnkd.in/gZm92Zdg
-
Two-time cancer survivor Diane Davis shares her story of strength, resilience, and hope. Despite a grim prognosis, her journey took a remarkable turn with the help of molecular profiling, advanced treatments, and a supportive network. This #OvarianCancerAwarenessMonth, Diane shares her experience to uplift and support others navigating similar battles. Learn more: https://lnkd.in/dqeXaA2X
Empowering others: Diane shares her cancer survival story and lessons learned
-
Connect with Caris during the Association of VA Hematology/Oncology Annual Meeting! Come by booth 508, network with our reps, and learn about the most advanced approach to molecular profiling. https://lnkd.in/dAC9g5cJ #AVAHO24
-
How can we predict response to cancer immunotherapy? Dr. Antoine Italiano from Institut Bergonié discussed how a survey of 200k Caris profiles showed that a tertiary lymphoid structure gene expression score (TLS score) is a robust predictor of ICI response. #ESMO24